Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 5/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | PYGM | P11217 | 1/20 | 0.43 |
| ▸ | P2RY6 | Q15077 | 5/20 | 0.41 |
| ▸ | P2RY14 | Q15391 | 3/20 | 0.41 |
| ▸ | TYMP | P19971 | 5/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.37 |
| ▸ | TK2 | O00142 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2583329 | 0.92 | TK1 (0.45) | TK1HSP90AA1PYGMP2RY6P2RY14 | |
| SCHEMBL2577536 | 0.90 | HSP90AA1 (0.44) | TK1HSP90AA1PYGMP2RY6TYMP | |
| SCHEMBL2585410 | 0.90 | PYGM (0.49) | TK1HSP90AA1PYGMP2RY6P2RY14 | |
| SCHEMBL2585662 | 0.90 | HSP90AA1 (0.56) | TK1HSP90AA1P2RY6P2RY14TYMP | |
| SCHEMBL2577261 | 0.90 | TK2 (0.46) | TK1HSP90AA1TK2 | |
| SCHEMBL2583952 | 0.90 | HSP90AA1 (0.43) | TK1HSP90AA1PYGMP2RY6P2RY14 | |
| SCHEMBL2584812 | 0.89 | TK1 (0.48) | TK1HSP90AA1TYMPTK2 | |
| SCHEMBL2577339 | 0.89 | P2RY2 (0.46) | TK1HSP90AA1TYMPP2RY2TK2 | |
| SCHEMBL2585316 | 0.88 | PYGM (0.52) | TK1HSP90AA1PYGMP2RY6P2RY14 | |
| SCHEMBL2583976 | 0.87 | HSP90AA1 (0.41) | TK1HSP90AA1TYMPP2RY2TK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269707-A1 | Modified nucleosides for the treatment of viral infections and abnormal cellullar proliferation | PHARMASSET, INC. | 2011-11-03 | — | — | US | disclosed |
| EP-1411954-B1 | MODIFIED NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION | PHARMASSET INC (US) | 2010-12-15 | — | — | EP | disclosed |
| EP-2251015-A1 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | Pharmasset, Inc. (US) | 2010-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269707-A1 | Modified nucleosides for the treatment of viral infections and abnormal cellullar proliferation | PNP, ALPP, XDH | TK1 35/4885HSP90AA1 4329/4885PYGM 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.